Combination Therapy for High-Risk Prostate Cancer
Name of the Trial
Why This Trial Is Important
No chemotherapy drug has been approved to treat newly diagnosed high-risk patients, who often get radiation therapy to kill cancer cells in and near the prostate, as well as hormone (antiandrogen) therapy to block the growth and spread of cancer cells that survive radiation.
In this trial, after initial radiation and hormone therapy, men with localized, high-risk, androgen-responsive prostate cancer will be treated with the drugs docetaxel and prednisone. Use of these drugs has improved survival - and was approved by the FDA - for patients with metastatic prostate cancer that is no longer responsive to androgens (androgen-independent disease).
"We hope docetaxel's ability to disrupt microtubule biology will prove effective against micrometastatic prostate disease," said Dr. Sandler. Microtubules are an important part of the machinery cells use to divide and multiply. "The other three major cancers - breast, colon, and lung - all respond to adjuvant chemotherapy, and such a treatment would be widely used by prostate patients."
Who Can Join This Trial
Study Sites and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.